Opioid Addiction | DecisionBase | US/EU5 | 2014

How Will Physicians and Payers Value Advances in Drug Delivery?

Opioid addiction is a debilitating, chronic relapsing disorder affecting nearly 5 million people in the seven major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). The buprenorphine/naloxone sublingual film (Reckitt Benckiser Pharmaceuticals’ Suboxone) was the patient- and market-share leader in 2012 owing to its familiarity to physicians and lack of administration restrictions compared with other opioid replacement therapies. Additional buprenorphine/naloxone formulations and the buprenorphine implant (Titan Pharmaceuticals/Braeburn Pharmaceuticals’ Probuphine) will offer delivery advantages over existing products; however, with limited drug development in opioid addiction, our surveyed psychiatrists and payers agree that significant opportunity remains for therapies that can offer improvement in reducing the use of opioids, as well as the risk of misuse, abuse, and diversion in this difficult-to-treat population.

Contact sales account_box

US 2014

Report

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…

north_east

Report

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…

north_east

Report

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…

north_east

Report

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…

north_east

Report

Biosimilars – Geographic Focus: China – Biosimilars – China In-Depth (China)

China’s biosimilar market has transformed significantly since February 2019, following the approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of Roche’s MabThera (rituximab). The…

north_east

Product logins

Opioid Addiction | DecisionBase | US/EU5 | 2014

Related Market Assessment Reports

Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)

Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)

Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)

Biosimilars – Geographic Focus: China – Biosimilars – China In-Depth (China)

Follow us

Contact us